

## Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

**Leiden, the Netherlands, July 16, 2026:** Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026.

Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT.

To participate in the conference call or to watch the live webcast, please register in advance using the links below.

### Conference call registration:

<https://register-conf.media-server.com/register/Bld285845cff504c39931913d279f646ea>

Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

*Please note, the Company will only take questions from dial-in attendees.*

### Webcast registration:

<https://edge.media-server.com/mmc/p/m35zejc7>

The webcast will also be accessible on the Pharming website at [Investors/Financial Documents & Reports](#), and a replay will be available shortly after the event.

### About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.

For more information, visit [www.pharming.com](http://www.pharming.com) and find us on [LinkedIn](#).

### For further public information, contact:

#### Pharming

Michael Levitan, VP Investor Relations and Capital Markets

T: +1 (908) 705 1696

E: [investor@pharming.com](mailto:investor@pharming.com)

Saskia Mehring, Head of Corporate Communications

T: +31 6 28 32 60 41

E: [media.relations@pharming.com](mailto:media.relations@pharming.com)

**Media Relations**

Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)

E: [jdeutsch@lyraadvisory.com](mailto:jdeutsch@lyraadvisory.com)

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)

T: +31 6 53 81 64 27